[Unconjugated pteridines and neuromeningeal infections]. 1993

P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
Service de Neurologie, CH Saint-Philibert, Lomme.

Concentrations of unconjugated pteridines (neopterin, monapterin, biopterin, pterin) were measured in the cerebrospinal fluid (CSF) of 310 patients, using a high performance liquid chromatography (HPCL) method. Our cohort included 209 controls (C), 15 patients with meningism (M), 22 with viral meningitis (VM), 17 with bacterial meningitis (BM), 9 with herpetic meningoencephalitis (HME), 2 with tuberculous meningoencephalitis (TME) and 36 with peripheral systemic infections (PI). These measurements, expressed as nmol/litre, showed a gradation of neopterin concentrations according to the type of infection: 20.1 + 6.5 in group C; 46.9 +/- 29.9 in group PI; 274.3 +/- 231.7 in group VM; 699.2 +/- 711.2 in group BM, 1,101.9 +/- 1,107.9 in group HME and 1,169 +/- 1,171.9 in group TME. There was no such gradation with biopterin. Comparisons of means showed that total concentrations in the pathology groups were very different from those observed in controls and in the neuromeningeal infections of the PI group. There was no correlation between the number of lymphocytes and the concentrations of neopterin or biopterin in the CSF. It is concluded that the concentration of neopterin in the CSF is a sensitive but little specific marker of infection, independent of CSF cellular reaction. Measuring this concentration makes it possible: 1) to evaluate the status of immune defences; 2) to predict that a meningitis will become chronic, and 3) to detect a possible parenchymal participation in a meningeal infection.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008580 Meningism A condition characterized by neck stiffness, headache, and other symptoms suggestive of meningeal irritation, but without actual inflammation of the meninges (MENINGITIS). Spinal fluid pressure may be elevated but spinal fluid is normal. (DeJong, The Neurologic Examination, 4th ed, p673) Dupre Syndrome,Meningismus,Pseudomeningitis,Dupre's Syndrome,Meningitis-Like Reaction,Dupres Syndrome,Meningisms,Meningitis Like Reaction,Meningitis-Like Reactions,Pseudomeningitides,Reaction, Meningitis-Like,Reactions, Meningitis-Like,Syndrome, Dupre,Syndrome, Dupre's
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008590 Meningoencephalitis An inflammatory process involving the brain (ENCEPHALITIS) and meninges (MENINGITIS), most often produced by pathogenic organisms which invade the central nervous system, and occasionally by toxins, autoimmune disorders, and other conditions. Cerebromeningitis,Encephalomeningitis,Cerebromeningitides,Encephalomeningitides,Meningoencephalitides
D011621 Pteridines Compounds based on pyrazino[2,3-d]pyrimidine which is a pyrimidine fused to a pyrazine, containing four NITROGEN atoms. 1,3,5,8-Tetraazanaphthalene,Pteridine,Pteridinone,Pyrazino(2,3-d)pyrimidine,Pyrazinopyrimidine,Pyrazinopyrimidines,Pyrimido(4,5-b)pyrazine,Pteridinones
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
January 1994, Revue neurologique,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
January 1970, Annual review of microbiology,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
January 1982, Survey of immunologic research,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
May 1982, Clinica chimica acta; international journal of clinical chemistry,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
December 1986, Clinica chimica acta; international journal of clinical chemistry,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
January 1967, Archiv fur Mikrobiologie,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
January 1990, Cancer chemotherapy and pharmacology,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
June 1980, Pathologie-biologie,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
January 1980, Methods in enzymology,
P Chatelet, and P Hautecoeur, and J L Dhondt, and G Forzy, and P Gallois, and J M Hayte, and P Warot, and J F Dereux
January 1988, Neuro-Chirurgie,
Copied contents to your clipboard!